Fe(II) and Tannic Acid-Cloaked MOF as Carrier of Artemisinin for Supply of Ferrous Ions to Enhance Treatment of Triple-Negative Breast Cancer

Abstract Suppression of tumor development by inducing ferroptosis may provide a potential remedy for triple-negative breast cancer, which is sensitive to intracellular oxidative imbalance. Recently, artemisinin (ART) and its derivatives have been investigated as potential anticancer agents for the t...

Full description

Bibliographic Details
Main Authors: Zihaoran Li, Xinghan Wu, Wenyu Wang, Chengcheng Gai, Weifen Zhang, Wentong Li, Dejun Ding
Format: Article
Language:English
Published: SpringerOpen 2021-02-01
Series:Nanoscale Research Letters
Subjects:
Online Access:https://doi.org/10.1186/s11671-021-03497-z
_version_ 1797760956987604992
author Zihaoran Li
Xinghan Wu
Wenyu Wang
Chengcheng Gai
Weifen Zhang
Wentong Li
Dejun Ding
author_facet Zihaoran Li
Xinghan Wu
Wenyu Wang
Chengcheng Gai
Weifen Zhang
Wentong Li
Dejun Ding
author_sort Zihaoran Li
collection DOAJ
description Abstract Suppression of tumor development by inducing ferroptosis may provide a potential remedy for triple-negative breast cancer, which is sensitive to intracellular oxidative imbalance. Recently, artemisinin (ART) and its derivatives have been investigated as potential anticancer agents for the treatment of highly aggressive cancers via the induction of ferroptosis by iron-mediated cleavage of the endoperoxide bridge. Owing to its poor water solubility and limited intracellular iron content, it is challenging for further application in antitumor therapy. Herein, we developed ferrous-supply nano-carrier for ART based on tannic acid (TA) and ferrous ion (Fe(II)) coated on the zeolitic imidazolate framework-8 (ZIF) with ART encapsulated (TA-Fe/ART@ZIF) via coordination-driven self-assembly. Drug release experiments showed that ART was not nearly released in pH 7.4, while 59% ART was released in pH 5.0 after 10 h, demonstrating the excellent pH-triggered release. Meanwhile, a high level of intracellular ROS and MDA, accompanied with decreasing GSH and GPX4, displayed a newly developed nano-drug system displayed markedly enhanced ferroptosis. Compared with monotherapy, in vitro and vivo tumor inhibition experiments demonstrated higher efficiency of tumor suppression of TA-Fe/ART@ZIF. This work provides a novel approach to enhance the potency of ferroptotic nano-medicine and new directions for TBNC therapy.
first_indexed 2024-03-12T19:06:59Z
format Article
id doaj.art-36306d23d1ef43e5a9d4c80b414a7086
institution Directory Open Access Journal
issn 1556-276X
language English
last_indexed 2024-03-12T19:06:59Z
publishDate 2021-02-01
publisher SpringerOpen
record_format Article
series Nanoscale Research Letters
spelling doaj.art-36306d23d1ef43e5a9d4c80b414a70862023-08-02T06:11:00ZengSpringerOpenNanoscale Research Letters1556-276X2021-02-0116111110.1186/s11671-021-03497-zFe(II) and Tannic Acid-Cloaked MOF as Carrier of Artemisinin for Supply of Ferrous Ions to Enhance Treatment of Triple-Negative Breast CancerZihaoran Li0Xinghan Wu1Wenyu Wang2Chengcheng Gai3Weifen Zhang4Wentong Li5Dejun Ding6Department of Pathology, Weifang Medical UniversityDepartment of Pathology, Weifang Medical UniversityCollege of Pharmacology, Weifang Medical UniversityDepartment of Pathology, Weifang Medical UniversityCollege of Pharmacology, Weifang Medical UniversityDepartment of Pathology, Weifang Medical UniversityCollege of Pharmacology, Weifang Medical UniversityAbstract Suppression of tumor development by inducing ferroptosis may provide a potential remedy for triple-negative breast cancer, which is sensitive to intracellular oxidative imbalance. Recently, artemisinin (ART) and its derivatives have been investigated as potential anticancer agents for the treatment of highly aggressive cancers via the induction of ferroptosis by iron-mediated cleavage of the endoperoxide bridge. Owing to its poor water solubility and limited intracellular iron content, it is challenging for further application in antitumor therapy. Herein, we developed ferrous-supply nano-carrier for ART based on tannic acid (TA) and ferrous ion (Fe(II)) coated on the zeolitic imidazolate framework-8 (ZIF) with ART encapsulated (TA-Fe/ART@ZIF) via coordination-driven self-assembly. Drug release experiments showed that ART was not nearly released in pH 7.4, while 59% ART was released in pH 5.0 after 10 h, demonstrating the excellent pH-triggered release. Meanwhile, a high level of intracellular ROS and MDA, accompanied with decreasing GSH and GPX4, displayed a newly developed nano-drug system displayed markedly enhanced ferroptosis. Compared with monotherapy, in vitro and vivo tumor inhibition experiments demonstrated higher efficiency of tumor suppression of TA-Fe/ART@ZIF. This work provides a novel approach to enhance the potency of ferroptotic nano-medicine and new directions for TBNC therapy.https://doi.org/10.1186/s11671-021-03497-zArtemisininFerroptosisTriple-negative breast cancerMetal–organic frameworksReactive oxygen species
spellingShingle Zihaoran Li
Xinghan Wu
Wenyu Wang
Chengcheng Gai
Weifen Zhang
Wentong Li
Dejun Ding
Fe(II) and Tannic Acid-Cloaked MOF as Carrier of Artemisinin for Supply of Ferrous Ions to Enhance Treatment of Triple-Negative Breast Cancer
Nanoscale Research Letters
Artemisinin
Ferroptosis
Triple-negative breast cancer
Metal–organic frameworks
Reactive oxygen species
title Fe(II) and Tannic Acid-Cloaked MOF as Carrier of Artemisinin for Supply of Ferrous Ions to Enhance Treatment of Triple-Negative Breast Cancer
title_full Fe(II) and Tannic Acid-Cloaked MOF as Carrier of Artemisinin for Supply of Ferrous Ions to Enhance Treatment of Triple-Negative Breast Cancer
title_fullStr Fe(II) and Tannic Acid-Cloaked MOF as Carrier of Artemisinin for Supply of Ferrous Ions to Enhance Treatment of Triple-Negative Breast Cancer
title_full_unstemmed Fe(II) and Tannic Acid-Cloaked MOF as Carrier of Artemisinin for Supply of Ferrous Ions to Enhance Treatment of Triple-Negative Breast Cancer
title_short Fe(II) and Tannic Acid-Cloaked MOF as Carrier of Artemisinin for Supply of Ferrous Ions to Enhance Treatment of Triple-Negative Breast Cancer
title_sort fe ii and tannic acid cloaked mof as carrier of artemisinin for supply of ferrous ions to enhance treatment of triple negative breast cancer
topic Artemisinin
Ferroptosis
Triple-negative breast cancer
Metal–organic frameworks
Reactive oxygen species
url https://doi.org/10.1186/s11671-021-03497-z
work_keys_str_mv AT zihaoranli feiiandtannicacidcloakedmofascarrierofartemisininforsupplyofferrousionstoenhancetreatmentoftriplenegativebreastcancer
AT xinghanwu feiiandtannicacidcloakedmofascarrierofartemisininforsupplyofferrousionstoenhancetreatmentoftriplenegativebreastcancer
AT wenyuwang feiiandtannicacidcloakedmofascarrierofartemisininforsupplyofferrousionstoenhancetreatmentoftriplenegativebreastcancer
AT chengchenggai feiiandtannicacidcloakedmofascarrierofartemisininforsupplyofferrousionstoenhancetreatmentoftriplenegativebreastcancer
AT weifenzhang feiiandtannicacidcloakedmofascarrierofartemisininforsupplyofferrousionstoenhancetreatmentoftriplenegativebreastcancer
AT wentongli feiiandtannicacidcloakedmofascarrierofartemisininforsupplyofferrousionstoenhancetreatmentoftriplenegativebreastcancer
AT dejunding feiiandtannicacidcloakedmofascarrierofartemisininforsupplyofferrousionstoenhancetreatmentoftriplenegativebreastcancer